Taking stock of the drug industry, from the lab to the medicine chestMarch 30, 2023Check out STAT+Sponsored ByBy Ed SilvermanPharmalot Columnist, Senior Writer Alex Hogan/STAT STAT+ | Solicitor general urges Supreme Court to review 'skinny labeling' and generic drug access The U.S. solicitor general urged the Supreme Court to review a controversy over generic drug access and "skinny labels" for medicines. By Ed Silverman STAT+ | Drug middlemen switch tactics, but the outcome is the same: high prices Prescription drug middlemen are shifting from rebates to increasingly larger administrative fees and specialty-generic markups. By John Wilkerson STAT+ | Former J&J exec, an in-demand free agent, takes the helm at privately held FogPharma Mammen, previously a candidate for the top job at Biogen, brings experience at both tiny biotech startups and multinational pharma giants. By Damian Garde Adobe Texas judge strikes down major Obamacare provision protecting preventive care The ruling deals a massive blow to President Biden's efforts to lower maternal and infant mortality rates and bolster reproductive rights. By Sarah Owermohle Listen: Biotech's monkey shortage, the broken generics market, & conference cancel culture This week, we explain how biotech is affected by a strange situation involving smuggled monkeys, international intrigue, and a criminal probe. By Damian Garde and Meg Tirrell and Adam Feuerstein More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2023, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
No comments